Most-Downgraded StocksMost-DowngradedNYSE:EW Edwards Lifesciences (EW) Stock Price, News & Analysis $67.26 -0.27 (-0.40%) (As of 09/19/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Edwards Lifesciences Stock (NYSE:EW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$67.14▼$69.0850-Day Range$59.70▼$90.9952-Week Range$58.93▼$96.12Volume7.11 million shsAverage Volume4.37 million shsMarket Capitalization$40.53 billionP/E Ratio28.99Dividend YieldN/APrice Target$79.82Consensus RatingHold Company OverviewEdwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.Read More… Trump’s weapon lurks in abandoned America (Ad)Unemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…Go here now to watch my new documentary Edwards Lifesciences Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 93rd PercentileEdwards Lifesciences scored higher than 93% of companies evaluated by MarketBeat, and ranked 80th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingEdwards Lifesciences has received a consensus rating of Hold. The company's average rating score is 2.48, and is based on 11 buy ratings, 15 hold ratings, and no sell ratings.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 22 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Edwards Lifesciences' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth3.33% Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 3.33% in the coming year, from $2.70 to $2.79 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 28.99, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.24.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 28.99, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 116.48.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 2.85. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 6.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Edwards Lifesciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.06% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently decreased by 1.26%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. Sustainability and ESG4.0 / 5Environmental Score-0.95 Percentage of Shares Shorted1.06% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently decreased by 1.26%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News Sentiment0.43 News SentimentEdwards Lifesciences has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Edwards Lifesciences this week, compared to 12 articles on an average week.Search InterestOnly 13 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,218,138.00 in company stock.Percentage Held by InsidersOnly 1.29% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Edwards Lifesciences' insider trading history. EW Stock News HeadlinesEdwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. Sells 5,000 SharesSeptember 13, 2024 | insidertrades.comInsider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 1,250 Shares of StockAugust 21, 2024 | insidertrades.com“I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!”Starting Monday, September 23 — a veteran 25-year Chicago Options Exchange market-maker will show you his UOA options secret that could help you consistently target gains of 126%… 245%… even 463% or more… Often in 30 days or less… No matter what the market is doing right now.September 19, 2024 | InvestorPlace (Ad)Jefferies Downgrades Edwards Lifesciences (EW)September 19 at 1:05 AM | msn.comEdwards Lifesciences: Solvable Problems Offer Excellent OpportunitiesSeptember 18 at 8:04 PM | seekingalpha.comEdwards Lifesciences: Hold Rating Amid TAVR Sector Challenges and Growth ConstraintsSeptember 18 at 3:04 PM | markets.businessinsider.comWells Fargo Sticks to Their Buy Rating for Edwards Lifesciences (EW)September 18 at 3:04 PM | markets.businessinsider.comHold Rating on Edwards Lifesciences Amidst Uncertain Growth and Market DynamicsSeptember 16 at 2:59 PM | markets.businessinsider.comSee More Headlines EW Stock Analysis - Frequently Asked Questions How have EW shares performed this year? Edwards Lifesciences' stock was trading at $76.25 at the beginning of the year. Since then, EW stock has decreased by 11.8% and is now trading at $67.26. View the best growth stocks for 2024 here. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Co. (NYSE:EW) announced its quarterly earnings results on Wednesday, July, 24th. The medical research company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. The firm's quarterly revenue was up 6.7% on a year-over-year basis. Read the conference call transcript. When did Edwards Lifesciences' stock split? Edwards Lifesciences shares split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were issued to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Does Edwards Lifesciences have any subsidiaries? The following companies are subsidiaries of Edwards Lifesciences: CAS Medical Systems, Harpoon Medical, Valtech Cardio, CardiAQ Valve Technologies, BMEYE, Embrella Cardiovascular, Myocor, and others. Who are Edwards Lifesciences' major shareholders? Top institutional shareholders of Edwards Lifesciences include Bank of New York Mellon Corp (3.28%), Legal & General Group Plc (0.89%), AustralianSuper Pty Ltd (0.46%) and American Century Companies Inc. (0.35%). Insiders that own company stock include Larry L Wood, Jean-Luc M Lemercier, Bernard J Zovighian, Kieran Gallahue, Donald E Bobo Jr, Catherine M Szyman, Scott B Ullem, Daveen Chopra, Heisz Leslie Stone, Martha H Marsh, Daniel J Lippis, Robert WA Sellers, Michael A Mussallem, Nicholas J Valeriani and Huimin Wang. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V) and Johnson & Johnson (JNJ). Company Calendar Last Earnings7/24/2024Today9/19/2024Next Earnings (Estimated)10/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical appliances & supplies Sub-IndustryHealth Care Equipment Current SymbolNYSE:EW CUSIP28176E10 CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees19,800Year Founded1958Price Target and Rating Average Stock Price Target$79.82 High Stock Price Target$106.00 Low Stock Price Target$57.00 Potential Upside/Downside+18.7%Consensus RatingHold Rating Score (0-4)2.48 Research Coverage27 Analysts Profitability EPS (Most Recent Fiscal Year)$2.32 Trailing P/E Ratio28.99 Forward P/E Ratio24.91 P/E Growth2.85Net Income$1.40 billion Net Margins24.55% Pretax Margin28.68% Return on Equity22.35% Return on Assets16.31% Debt Debt-to-Equity Ratio0.08 Current Ratio3.71 Quick Ratio2.87 Sales & Book Value Annual Sales$6.20 billion Price / Sales6.53 Cash Flow$2.72 per share Price / Cash Flow24.70 Book Value$11.08 per share Price / Book6.07Miscellaneous Outstanding Shares602,600,000Free Float594,826,000Market Cap$40.53 billion OptionableOptionable Beta1.13 Social Links Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 9, 2024. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com. Edwards Lifesciences Bull Case Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.: Edwards Lifesciences Co. has a strong track record of consistent revenue growth, indicating stability and potential for future earnings. The company's recent earnings report beat analyst estimates, showcasing strong financial performance and positive outlook. With a current stock price of $70.88, there may be an opportunity for investors to buy at a potentially undervalued level. Edwards Lifesciences Co. operates in the structural heart disease and critical care monitoring sectors, which are essential and growing areas in the healthcare industry. The company's moderate buy consensus rating and price target of $81.10 suggest positive sentiment and potential upside for investors. Edwards Lifesciences Bear Case Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons: Edwards Lifesciences Co.'s stock has experienced a recent decline of 0.6%, indicating potential volatility and market uncertainty. The company's price-to-earnings ratio of 30.55 and price-to-earnings-growth ratio of 2.57 may suggest a relatively high valuation compared to industry peers. Insiders have sold a significant number of company shares in the last ninety days, potentially signaling lack of confidence or future challenges. Several equities research analysts have issued hold ratings on the stock, indicating mixed opinions on its future performance. The company's debt-to-equity ratio of 0.08 may raise concerns about its financial leverage and risk exposure. This page (NYSE:EW) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredForget ChatGPT: Follow the AI Retirement PlaybookEveryone’s talking about AI right now, but I’ve been talking about it for years. Follow this two-part playb...Brownstone Research | SponsoredDump Nvidia, Apple, and Tesla Before It’s Too LateThe financial world is on high alert. Billionaires like Warren Buffett, Jeff Bezos, and Elon Musk are dumpi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Edwards Lifesciences Co. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Edwards Lifesciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.